1-(N-Butylcarbamoyl)-4-methyl-piperazin | 1461-80-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-(N-Butylcarbamoyl)-4-methyl-piperazin
• 英文别名: 4-methyl-piperazine-1-carboxylic acid butylamide；N-butyl-4-methylpiperazine-1-carboxamide
• CAS: 1461-80-9
• 化学式: C₁₀H₂₁N₃O
• mdl: MFCD06088695
• 分子量: 199.296
• InChiKey: VBPCMMWOYIHEBM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  35.6
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] QUINDOLINE COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS DE QUINDOLINE ET LEURS UTILISATIONS
  申请人：UNIV ARIZONA

  公开号：WO2020160175A1

  公开（公告）日：2020-08-06

  This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a quindoline (or similar) structure which function as stabilizers of G-quadruplex (G4) formation, and their use as therapeutics for the treatment of cancer (e.g., castration-resistant prostate cancer), and other conditions mediated by G4 stabilization.

  这项发明属于药物化学领域。具体而言，该发明涉及一类新型具有喹啉（或类似）结构的小分子，其作为G-四链体（G4）形成的稳定剂，并且它们作为治疗癌症（例如去势抵抗性前列腺癌）和其他通过G4稳定介导的疾病的治疗药物的用途。
• Compounds for stabilizing ryanodine receptors from aberrant levels of calcium release
  申请人：Rosalind Franklin University of Medicine and Science

  公开号：US10011578B2

  公开（公告）日：2018-07-03

  Disclosed herein are methods and compositions comprising compounds capable of normalizing neuronal calcium dyshomeostasis. Also disclosed are methods comprising these compounds for treating neuronal or neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, fronto-temporal dementia, Pick's disease, chronic traumatic encepholopathy, traumatic brain injury, stroke, cerebellar ataxia, multiple sclerosis, Down syndrome, and aging-related CNS disorders.

  本文公开了包含能够使神经元钙平衡失调正常化的化合物的方法和组合物。还公开了包含这些化合物的用于治疗神经元或神经系统疾病的方法，包括阿尔茨海默病、帕金森病、亨廷顿病、前颞叶痴呆症、皮克病、慢性创伤性脑萎缩、脑外伤、中风、小脑共济失调、多发性硬化症、唐氏综合征和衰老相关的中枢神经系统疾病。
• Novel tetracyclic tetrahydrofuran derivatives
  申请人：Cid-Nunez Maria Jose

  公开号：US20070191469A1

  公开（公告）日：2007-08-16

  This invention concerns novel substituted unsaturated tetracyclic tetrahydrofuran derivatives with binding affinities towards serotonine receptors, in particular 5-HT 2A and 5-HT 2C receptors, and towards dopamine receptors, in particular dopamine D2 receptors and with norepinephrine reuptake inhibition properties, pharmaceutical compositions comprising the compounds according to the invention, the use thereof as a medicine, in particular for the prevention and/or treatment of a range of psychiatric and neurological disorders, in particular certain psychotic, cardiovascular and gastrokinetic disorders and processes for their production. The compounds according to the invention can be represented by general Formula (I) and comprises also the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the N-oxide form thereof and prodrugs thereof, wherein all substitutents are defined as in Claim 1.
• NOVEL UNSATURATED TETRACYCLIC TETRAHYDROFURAN DERIVATIVES
  申请人：Núñez José Maria

  公开号：US20120035170A1

  公开（公告）日：2012-02-09

  This invention concerns novel substituted unsaturated tetracyclic tetrahydrofuran derivatives with binding affinities towards serotonine receptors, in particular 5-HT 2A and 5-HT 2C receptors, and towards dopamine receptors, in particular dopamine D2 receptors and with norepinephrine reuptake inhibition properties, pharmaceutical compositions comprising the compounds according to the invention, the use thereof as a medicine, in particular for the prevention and/or treatment of a range of psychiatric and neurological disorders, in particular certain psychotic, cardiovascular and gastrokinetic disorders and processes for their production. The compounds according to the invention can be represented by general Formula (I) and comprises also the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the N-oxide form thereof and prodrugs thereof, wherein all substituents are defined as in claim 1.
• US8022102B2
  申请人：——

  公开号：US8022102B2

  公开（公告）日：2011-09-20